Prestige Consumer Healthcare (NYSE:PBH) & MacroGenics (NASDAQ:MGNX) Head-To-Head Analysis

Prestige Consumer Healthcare (NYSE:PBH) and MacroGenics (NASDAQ:MGNX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Volatility and Risk

Prestige Consumer Healthcare has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Comparatively, MacroGenics has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Prestige Consumer Healthcare and MacroGenics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prestige Consumer Healthcare	0	3	3	0	2.50
MacroGenics	0	4	2	1	2.57

Prestige Consumer Healthcare presently has a consensus price target of $93.3333, indicating a potential upside of 42.53%. MacroGenics has a consensus price target of $3.60, indicating a potential upside of 150.00%. Given MacroGenics’ stronger consensus rating and higher probable upside, analysts plainly believe MacroGenics is more favorable than Prestige Consumer Healthcare.

Earnings and Valuation

This table compares Prestige Consumer Healthcare and MacroGenics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prestige Consumer Healthcare	$1.14 billion	2.83	$214.60 million	$4.26	15.37
MacroGenics	$149.96 million	0.61	-$66.97 million	($0.57)	-2.53

Prestige Consumer Healthcare has higher revenue and earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Prestige Consumer Healthcare and MacroGenics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prestige Consumer Healthcare	19.02%	12.69%	6.79%
MacroGenics	-21.99%	-40.24%	-14.62%

Insider and Institutional Ownership

100.0% of Prestige Consumer Healthcare shares are held by institutional investors. Comparatively, 96.9% of MacroGenics shares are held by institutional investors. 1.4% of Prestige Consumer Healthcare shares are held by insiders. Comparatively, 13.0% of MacroGenics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Prestige Consumer Healthcare beats MacroGenics on 10 of the 15 factors compared between the two stocks.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

About MacroGenics

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.